Table 4 Summary of findings 2: biological treatments compared to placebo for Psoriatic Arthritis—serious adverse events
Summary of findings | ||||||
|---|---|---|---|---|---|---|
Biological treatment effects to serious adverse events outcome in the treatment of Psoriatic Arthritis patients | ||||||
Population: Psoriatic Arthritis patients Intervention: Biological treatments (Adalimumab, Etanercept, Infliximab, Golimumab, Secukinumab, Certolizumab pegol) and synthetic target-specific drugs (Tofacitinib) Comparator (reference): Placebo |
| |||||
Biological treatments | Anticipated absolute effect* (95% CI) | Relative Effect (95% CI) | № of participants (studies) | Certainty of evidence (GRADE) | Ranking | |
Without intervention | With intervention | |||||
Golimumab | 4 per 100 | 1 per 100 (0–13) | RR 0.34 (0.04–3.17) | 93 (2 RCTs) | ⨁◯◯◯ Very low | 1º - P-score = 0.83 |
Secukinumab | 4 per 100 | 3 per 100 (2–5) | RR 0.85 (0.59–1.23) | 2706 (7 RCTs) | ⨁⨁◯◯ Low | 2º - P-score = 0.64 |
Adalimumab | 2 per 100 | 2 per 100 (1–3) | RR 0.89 (0.59–1.34) | 1957 (6 RCTs) | ⨁◯◯◯ Very low | 3º - P-score = 0.60 |
Etanercept | 4 per 100 | 3 per 100 (1–11) | RR 0.86 (0.25–3.01) | 265 (2 RCTs) | ⨁◯◯◯ Very low | 4º - P-score = 0.58 |
Tofacitinib | 2 per 100 | 2 per 100 (1–8) | RR 1.23 (0.30–5.00) | 474 (2 RCTs) | ⨁◯◯◯ Very low | 5º - P-score = 0.41 |
Infliximab | 1 per 100 | 2 per 100 (0–15) | RR 2.00 (0.26–15.24) | 214 (2 RCTs) | ⨁◯◯◯ Very low | 6º - P-score = 0.26 |
Certolizumab pegol | 4 per 100 | 8 per 100 (3–19) | RR 1.74 (0.72–4.22) | 409 (1 RCT) | ⨁⨁◯◯ Low | 7º - P-score = 0.20 |
Placebo | – | – | Reference comparator | – | – | – |
